Taysha Gene Therapies Inc (NAS:TSHA)
$ 3.43 0.3 (9.58%) Market Cap: 641.47 Mil Enterprise Value: 578.20 Mil PE Ratio: 0 PB Ratio: 11.91 GF Score: 29/100

Taysha Gene Therapies Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 09, 2021 / 09:00PM GMT
Release Date Price: $20.09 (+1.36%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Great. Good afternoon, everybody, and thanks for joining us for our last session here today. Very pleased to have Taysha with us.

Before we get started, I just need to read a quick disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/research disclosures.

So pleased to have a broad range of the management team here. We have RA Session, the CEO; Suyash Prasad, who's the CMO. I think that's your title, Suyash, sorry; and Kamran Alam.

Questions & Answers

Matthew Kelsey Harrison;R. A.
Morgan Stanley, Research Division - Executive Director

I thought maybe a good place to start because it's so recent is just the FDA obviously had their 2-day hearing on AAV. So I thought maybe you guys could just comment on what you thought are the key takeaways from that and any implications you see from that.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot